EUCTR2016-002940-17-NL进行中（未招募）1 期
eoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer
Antoni van Leeuwenhoek0 个研究点目标入组 155 人开始时间: 2016年9月19日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 155
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Study population. In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Stage 2-3 (>T3 and/or N+) adenocarcinoma of the colon (and rectosigmoid considered as non-rectal and not undergoing neoadjuvant treatment) for the MSI cohort;
- •- No signs of distant metastases on CT-scan and physical examination;
- •- No clinical obstruction;
- •- No clinical symptoms or radiological suspicion of perforation;
- •Colonoscopy must be performed after registration to obtain study-specific biopsies. If biopsies are not possible, patients cannot be included in the study;
- •WHO performance status of 0 or 1;
- •Screening laboratory tests must meet the following criteria and should be obtained within 7 days prior to randomization/registration: WBC > 2.0 x 10^9/L, ANC > 1.5x10^9/L, platelets > 100 x 10^9/L, Hemoglobin > 5.0mmol/L. Transfusion is allowed to obtain an adequate hemoglobin level. Liver function tests: total bilirubin < 1.5 upper limit of normal (ULN) (except for subjects with Gilbert syndrome, who can have total bilirubin <3.0 mg/dL); alkaline phosphatase <2.5 ULN; transaminases (ASAT/ALAT) <3 x ULN; LDH < 2 x ULN;
- •Creatinine clearance (Cockcroft-Gault) of >40 ml/min;
- •Women of childbearing potential (WOCBP)* must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug;
- •Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab;
- •Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception;
- •CT-scan must be performed within 28 days prior to registration;
- •No previous treatment with immune checkpoint inhibitors targeting including but not limited to CTLA-4, PD-1 or PD-L1;
- •No previous treatment with chemotherapy;
- •- No radiotherapy prior to or planned post-surgery radiotherapy;
- •- Allergies and Adverse Drug Reaction:
- •No history of allergy to study drug components
- •No history of severe hypersensitivity reaction to any monoclonal antibody
- •- No intercurrent illnesses, including but not limited to infections, unstable angina pectoris
- •- No underlying medical conditions that, in the Investigator’s opinion, will make the administration of the study drug hazardous or obscure the interpretation of toxicity determination of adverse events;
- •- No positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection;
- •- No history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- •- No active autoimmune disease or a documented history of autoimmune disease, or other medical conditions requiring systemic steroid or immunosuppressive medications, except for subjects with vitiligo, diabetes mellitus type 1, residual hypothyroidism due to autoimmune condition only requiring hormone replac
排除标准
- •Study population. In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •Stage 2-3 (>T3 and/or N+) adenocarcinoma of the colon (and rectosigmoid considered as non-rectal and not undergoing neoadjuvant treatment) for the MSI cohort;
- •- No signs of distant metastases on CT-scan and physical examination;
- •- No clinical obstruction;
- •- No clinical symptoms or radiological suspicion of perforation;
- •Colonoscopy must be performed after registration to obtain study-specific biopsies. If biopsies are not possible, patients cannot be included in the study;
- •WHO performance status of 0 or 1;
- •Screening laboratory tests must meet the following criteria and should be obtained within 7 days prior to randomization/registration: WBC > 2.0 x 10^9/L, ANC > 1.5x10^9/L, platelets > 100 x 10^9/L, Hemoglobin > 5.0mmol/L. Transfusion is allowed to obtain an adequate hemoglobin level. Liver function tests: total bilirubin < 1.5 upper limit of normal (ULN) (except for subjects with Gilbert syndrome, who can have total bilirubin <3.0 mg/dL); alkaline phosphatase <2.5 ULN; transaminases (ASAT/ALAT) <3 x ULN; LDH < 2 x ULN;
- •Creatinine clearance (Cockcroft-Gault) of >40 ml/min;
- •Women of childbearing potential (WOCBP)* must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug;
- •Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab;
- •Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception;
- •CT-scan must be performed within 28 days prior to registration;
- •No previous treatment with immune checkpoint inhibitors targeting including but not limited to CTLA-4, PD-1 or PD-L1;
- •No previous treatment with chemotherapy;
- •- No radiotherapy prior to or planned post-surgery radiotherapy;
- •- Allergies and Adverse Drug Reaction:
- •No history of allergy to study drug components
- •No history of severe hypersensitivity reaction to any monoclonal antibody
- •- No intercurrent illnesses, including but not limited to infections, unstable angina pectoris
- •- No underlying medical conditions that, in the Investigator’s opinion, will make the administration of the study drug hazardous or obscure the interpretation of toxicity determination of adverse events;
- •- No positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection;
- •- No history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
- •- No active autoimmune disease or a documented history of autoimmune disease, or other medical conditions requiring systemic steroid or immunosuppressive medications, except for subjects with vitiligo, diabetes mellitus type 1, residual hypothyroidism due to autoimmune condition only requiring hormone replac
研究者
相似试验
招募中
2 期
eoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer. The NICHE trial.NL-OMON53138ederlands Kanker Instituut268
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
进行中（未招募）
1 期
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
招募中
4 期
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
尚未招募
Unknown
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.JPRN-UMIN000050723Kobe University200